Date:11/13/2012

occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com 
jrando@tiberend.com

 

'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. AspenBio to Present at 2012 Aegis Healthcare Conference
2. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
5. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
6. Regulus to Present at the Lazard Capital Markets Healthcare Conference
7. Heptares to Present at BIO-Europe 2012
8. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
9. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Organovo To Present At Lazard Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference